Mellen Center for Multiple Sclerosis Treatment and Research
Richard A. Rudick has not added Biography.
If you are Richard A. Rudick and would like to personalize this page please email our Author Liaison for assistance.
Sex differences in cytokine responses to myelin peptides in multiple sclerosis.
Journal of neuroimmunology Sep, 2002 | Pubmed ID: 12225904
Factors that predict health-related quality of life in patients with relapsing-remitting multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) Feb, 2003 | Pubmed ID: 12617260
Flow cytometric analysis of chemokine receptor expression on cerebrospinal fluid leukocytes.
Methods (San Diego, Calif.) Apr, 2003 | Pubmed ID: 12725798
Expression of CCR2, CCR5, and CXCR3 by CD4+ T cells is stable during a 2-year longitudinal study but varies widely between individuals.
Journal of neurovirology Jun, 2003 | Pubmed ID: 12775413
Interferons in relapsing remitting multiple sclerosis.
Lancet May, 2003 | Pubmed ID: 12781561
Interferon gamma responses to myelin peptides in multiple sclerosis correlate with a new clinical measure of disease progression.
Journal of neuroimmunology Aug, 2003 | Pubmed ID: 12965264
Interferon-beta 1a does not reduce expression of CCR5 and CXCR3 on circulating T cells.
Journal of neuroimmunology Aug, 2003 | Pubmed ID: 12965266
Biologic impact of interferon antibodies, and complexities in assessing their clinical significance.
Neurology Nov, 2003 | Pubmed ID: 14610110
Atrophy is detectable within a 3-month period in untreated patients with active relapsing remitting multiple sclerosis.
Archives of neurology Dec, 2003 | Pubmed ID: 14676048
Multiple sclerosis: disease markers accelerate progress.
Lancet neurology Jan, 2004 | Pubmed ID: 14693099
Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosis.
Journal of neuroimaging : official journal of the American Society of Neuroimaging Jul, 2004 | Pubmed ID: 15228760
Defining interferon beta response status in multiple sclerosis patients.
Annals of neurology Oct, 2004 | Pubmed ID: 15389896
Association of fatigue and brain atrophy in multiple sclerosis.
Journal of the neurological sciences Feb, 2005 | Pubmed ID: 15694198
Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications.
Multiple sclerosis (Houndmills, Basingstoke, England) Apr, 2005 | Pubmed ID: 15794385
Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
Expert review of neurotherapeutics Jul, 2004 | Pubmed ID: 15853576
Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) Aug, 2005 | Pubmed ID: 16042223
Effects of sex hormones on costimulatory molecule expression in multiple sclerosis.
Journal of neuroimmunology Oct, 2005 | Pubmed ID: 16046001
Primary progressive multiple sclerosis as a phenotype of a PLP1 gene mutation.
Annals of neurology Sep, 2005 | Pubmed ID: 16130097
Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity.
Archives of neurology Sep, 2005 | Pubmed ID: 16157744
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
The New England journal of medicine Mar, 2006 | Pubmed ID: 16510745
Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal study.
Annals of neurology Aug, 2006 | Pubmed ID: 16786526
Should patients with relapsing multiple sclerosis be given a higher dose and frequency of interferon-beta1a?
Nature clinical practice. Neurology Nov, 2005 | Pubmed ID: 16932486
Drug Insight: interferon treatment in multiple sclerosis.
Nature clinical practice. Neurology Jan, 2006 | Pubmed ID: 16932519
Chemokine receptors as biomarkers in multiple sclerosis.
Disease markers , 2006 | Pubmed ID: 17124344
Imaging correlates of axonal swelling in chronic multiple sclerosis brains.
Annals of neurology Sep, 2007 | Pubmed ID: 17427920
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring.
Lancet neurology May, 2007 | Pubmed ID: 17434098
Interferon-beta for multiple sclerosis: Long-term benefits?
Annals of neurology Apr, 2007 | Pubmed ID: 17444503
Developing a mentorship program for clinical researchers.
The Journal of continuing education in the health professions , 2007 | Pubmed ID: 17576629
Health-related quality of life in multiple sclerosis: effects of natalizumab.
Annals of neurology Oct, 2007 | Pubmed ID: 17696126
Novel interferon-beta-induced gene expression in peripheral blood cells.
Journal of leukocyte biology Nov, 2007 | Pubmed ID: 17709400
Interferon-beta treatment for multiple sclerosis.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics Oct, 2007 | Pubmed ID: 17920544
Biomarkers for interferon response in MS: are we there yet?
Neurology Mar, 2008 | Pubmed ID: 18362268
Gray matter atrophy in multiple sclerosis: a longitudinal study.
Annals of neurology Sep, 2008 | Pubmed ID: 18661561
LINGO-1 antagonists as therapy for multiple sclerosis: in vitro and in vivo evidence.
Expert opinion on biological therapy Oct, 2008 | Pubmed ID: 18774923
Health-related quality of life in multiple sclerosis: current evidence, measurement and effects of disease severity and treatment.
CNS drugs , 2008 | Pubmed ID: 18788835
Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS.
Journal of the neurological sciences Jul, 2009 | Pubmed ID: 19100997
Brain atrophy as an outcome measure for multiple sclerosis clinical trials: a "no-brainer"?
Neurology Feb, 2009 | Pubmed ID: 19221291
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.
Journal of neurology Mar, 2009 | Pubmed ID: 19308305
Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis.
Lancet neurology Jun, 2009 | Pubmed ID: 19446274
Disease modification in multiple sclerosis: issues with relevance to clinical trial designs in Alzheimer's disease.
Alzheimer's & dementia : the journal of the Alzheimer's Association Jul, 2006 | Pubmed ID: 19595872
Natalizumab for the treatment of relapsing multiple sclerosis.
Biologics : targets & therapy Jun, 2008 | Pubmed ID: 19707353
Gray-matter injury in multiple sclerosis.
The New England journal of medicine Oct, 2009 | Pubmed ID: 19812410
Do interferon beta-1b and glatiramer acetate grow brain?
Lancet neurology Dec, 2009 | Pubmed ID: 19909906
Heterogeneous, longitudinally stable molecular signatures in response to interferon-beta.
Annals of the New York Academy of Sciences Dec, 2009 | Pubmed ID: 20074275
Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.
Journal of the neurological sciences May, 2010 | Pubmed ID: 20236661
A radical proposal: integrate clinical investigation into the U.S. health care system.
Science translational medicine Oct, 2009 | Pubmed ID: 20368168
Patient-centered outcomes: translating clinical efficacy into benefits on health-related quality of life.
Neurology Apr, 2010 | Pubmed ID: 20421570
The multiple sclerosis functional composite: a clinically meaningful measure of disability.
Neurology Apr, 2010 | Pubmed ID: 20421572
Validation of a self-report comorbidity questionnaire for multiple sclerosis.
Neuroepidemiology Aug, 2010 | Pubmed ID: 20551692
Measuring disability in relapsing-remitting MS.
Neurology Jul, 2010 | Pubmed ID: 20592252
Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: eight-year follow-up.
Archives of neurology Nov, 2010 | Pubmed ID: 20625068
Assessment of JC virus DNA in blood and urine from natalizumab-treated patients.
Annals of neurology Sep, 2010 | Pubmed ID: 20737514
Multiple sclerosis: is multiple sclerosis caused by venous insufficiency?
Nature reviews. Neurology Sep, 2010 | Pubmed ID: 20811464
Possible clinical outcome measures for clinical trials in patients with multiple sclerosis.
Therapeutic advances in neurological disorders Jul, 2010 | Pubmed ID: 21179614
Web-based self-management for patients with multiple sclerosis: a practical, randomized trial.
Telemedicine journal and e-health : the official journal of the American Telemedicine Association Jan-Feb, 2011 | Pubmed ID: 21214498
Diagnostic criteria in multiple sclerosis: headed in the right direction but still a ways to go.
Annals of neurology Feb, 2011 | Pubmed ID: 21387367
Beta-interferon for multiple sclerosis.
Experimental cell research May, 2011 | Pubmed ID: 21396360
Challenges to clinical trials in multiple sclerosis: outcome measures in the era of disease-modifying drugs.
Current opinion in neurology Jun, 2011 | Pubmed ID: 21455068
Excessive biologic response to IFNβ is associated with poor treatment response in patients with multiple sclerosis.
PloS one , 2011 | Pubmed ID: 21602934
Oral treatment for multiple sclerosis.
Lancet neurology Nov, 2011 | Pubmed ID: 22014437
The role of cell type-specific responses in IFN-β therapy of multiple sclerosis.
Proceedings of the National Academy of Sciences of the United States of America Dec, 2011 | Pubmed ID: 22106296
Multiple sclerosis, natalizumab, and PML: helping patients decide.
Cleveland Clinic journal of medicine Nov, 2011 | Pubmed ID: 22123928
Risk stratification and patient counseling for natalizumab in multiple sclerosis.
Neurology Feb, 2012 | Pubmed ID: 22282644
MS clinical trials: what can subgroup analyses teach us?
Lancet neurology May, 2012 | Pubmed ID: 22494954
The elusive biomarker for personalized medicine in multiple sclerosis: the search continues.
Neurology Aug, 2012 | Pubmed ID: 22573625
Multiple sclerosis or multiple possibilities: the continuing problem of misdiagnosis.
Neurology Jun, 2012 | Pubmed ID: 22581931
Early tolerability and safety of fingolimod in clinical practice.
Journal of the neurological sciences Dec, 2012 | Pubmed ID: 23040960
Measurement and clinical effect of grey matter pathology in multiple sclerosis.
Lancet neurology Dec, 2012 | Pubmed ID: 23153407
Time to integrate clinical and research informatics.
Science translational medicine Nov, 2012 | Pubmed ID: 23197569
Predictors of long-term outcome in multiple sclerosis patients treated with interferon β.
Annals of neurology Jan, 2013 | Pubmed ID: 23378325
Author response.
Neurology Feb, 2013 | Pubmed ID: 23544194
Author response to comment on "time to integrate clinical and research informatics".
Science translational medicine Apr, 2013 | Pubmed ID: 23552368
Reliability of classifying multiple sclerosis disease activity using magnetic resonance imaging in a multiple sclerosis clinic.
JAMA neurology Mar, 2013 | Pubmed ID: 23599930
MRI lesions: a surrogate for relapses in multiple sclerosis?
Lancet neurology Jul, 2013 | Pubmed ID: 23743083
Preventing brain atrophy should be the gold standard of effective therapy in MS (after the first year of treatment): Yes.
Multiple sclerosis (Houndmills, Basingstoke, England) Jul, 2013 | Pubmed ID: 23818018
Multiple Sclerosis Outcome Assessments Consortium: Genesis and initial project plan.
Multiple sclerosis (Houndmills, Basingstoke, England) Jan, 2014 | Pubmed ID: 24057430
Assessing treatment response to interferon-β: is there a role for MRI?
Neurology Jan, 2014 | Pubmed ID: 24336144
Defining the clinical course of multiple sclerosis: The 2013 revisions.
Neurology May, 2014 | Pubmed ID: 24871874
Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study.
Neurology Jun, 2014 | Pubmed ID: 24898925
ACERCA DE JoVE
Copyright © 2024 MyJoVE Corporation. Todos los derechos reservados